Please login to be able to save your searches and receive alerts for new content matching your search criteria.
NEWS – Lilly and Innovent Biologics enter strategic alliance; one of the largest biotech drug development collaborations in China.
NEWS – ZAI Lab enrolls first patient in Phase 1 study of ZL-2102.
NEWS – LamdaGen Corporation launches Taiwan diagnostic subsidiary.
NEWS – 3M makes a greater commitment in China's West Region; Plans for a new customer technical center.
NEWS – NCKU launches campus food ingredients registration platform.
NEWS – Lab-free immune therapy developed.
NEWS – Hainan Province, Hengda Health and Korean Yuanchen enter strategic cooperation agreement.
NEWS – Bristol-Myers Squibb and ZAI Lab enter licensing agreement to develop, manufacture and commercialize brivanib in China.
NEWS – Concord Medical acquires Fortis Surgical Hospital in Singapore.
NEWS – Merck Animal Health and China Animal Husbandry Industry Co., Ltd establish partnership.
NEWS – Helsinn Group signs exclusive agreement with Mundipharma for distribution and license of anamorelin in China, Hong Kong and Macau.
NEWS – C-FDA approves IND for D-Pharm's anti-epileptic drug, DP-VPA in China.
NEWS – Waters' UPLC I-Class/Xevo TQ-S System approved for in vitro diagnostic use in China.
NEWS – Vitruvias Therapeutics and Sunny Pharmtech form partnership to co-develop several high value generic drugs.
NEWS – Professor Xie Xiaoliang first Chinese Albany Award winner.
RESEARCH INSTITUTES – A look at Duke Kunshan University Global Health Research Center.
RESEARCH INSTITUTES – The NYU-ECNU Institute of Brain and Cognitive Science.
In this paper, I continue the study of the mathematical models presented in [J. C. Larsen, Models of cancer growth, J. Appl. Math. Comput.53(1–2) (2015) 613–645] and [J. C. Larsen, The bistability theorem in a model of metastatic cancer, to appear in Appl. Math.]. I shall prove the bistability theorem for the ODE model from [Larsen, 2015]. It is a mass action kinetic system in the variables CC cancer, GF growth factor and GI growth inhibitor. This theorem says that for some values of the parameters, there exist two positive singular points c+∗=(C+∗,GF∗,GI+∗)c+∗=(C+∗,GF∗,GI+∗), c−∗=(C−∗,GF∗,GI−∗)c−∗=(C−∗,GF∗,GI−∗) of the vector field. Here C−∗<C+∗C−∗<C+∗ and c−∗c−∗ is stable and c+∗c+∗ is unstable, see Sec. 2. There is also a discrete model in [Larsen, 2015], it is a linear map (TT) on three-dimensional Euclidean vector space with variables (C,GF,GI),(C,GF,GI), where these variables have the same meaning as in the ODE model above. In [Larsen, 2015], I showed that one can sometimes find affine vector fields on three-dimensional Euclidean vector space whose time one map is TT. I shall also show this in the present paper in a more general setting than in [Larsen, 2015]. This enables me to find an expression for the rate of change of cancer growth on the coordinate hyperplane C=0C=0 in Euclidean vector space. I also present an ODE model of cancer metastasis with variables C,CM,GF,GI,C,CM,GF,GI, where CC is primary cancer and CMCM is metastatic cancer and GF, GI are growth factors and growth inhibitors, respectively.